ARRY-371797: Phase II data

An open-label, U.S. Phase II trial in 9 evaluable patients with symptomatic dilated cardiomyopathy due to an LMNA gene mutation showed that twice-daily oral ARRY-797 improved mean 6MWT distance from b...